CN105687297B - Mung bean extract and preparation method thereof - Google Patents
Mung bean extract and preparation method thereof Download PDFInfo
- Publication number
- CN105687297B CN105687297B CN201610089202.7A CN201610089202A CN105687297B CN 105687297 B CN105687297 B CN 105687297B CN 201610089202 A CN201610089202 A CN 201610089202A CN 105687297 B CN105687297 B CN 105687297B
- Authority
- CN
- China
- Prior art keywords
- extract
- mung bean
- filtering
- semen phaseoli
- phaseoli radiati
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 240000004922 Vigna radiata Species 0.000 title claims abstract description 64
- 235000010721 Vigna radiata var radiata Nutrition 0.000 title claims abstract description 64
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 title claims abstract description 64
- 229940069765 bean extract Drugs 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title description 8
- 239000000284 extract Substances 0.000 claims abstract description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000000706 filtrate Substances 0.000 claims abstract description 28
- 229920002472 Starch Polymers 0.000 claims abstract description 26
- 235000019698 starch Nutrition 0.000 claims abstract description 26
- 239000008107 starch Substances 0.000 claims abstract description 26
- 238000001914 filtration Methods 0.000 claims abstract description 24
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 20
- 229930003944 flavone Natural products 0.000 claims abstract description 20
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 20
- 235000011949 flavones Nutrition 0.000 claims abstract description 20
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 210000000582 semen Anatomy 0.000 claims abstract description 17
- 238000001035 drying Methods 0.000 claims abstract description 16
- 238000002156 mixing Methods 0.000 claims abstract description 12
- 238000000227 grinding Methods 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 238000005406 washing Methods 0.000 claims abstract description 8
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 208000010668 atopic eczema Diseases 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000002002 slurry Substances 0.000 claims description 4
- 230000001139 anti-pruritic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 208000003251 Pruritus Diseases 0.000 abstract description 12
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 11
- 230000007803 itching Effects 0.000 abstract description 8
- 208000030961 allergic reaction Diseases 0.000 abstract description 6
- 241000699670 Mus sp. Species 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010014025 Ear swelling Diseases 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 210000005069 ears Anatomy 0.000 description 5
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 5
- 229960000645 histamine hydrochloride Drugs 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229940127021 low-dose drug Drugs 0.000 description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- NYYDYGUNUWVDRV-UHFFFAOYSA-N CC(=O)C.[N+](=O)([O-])C1=C(C=CC(=C1)[N+](=O)[O-])Cl Chemical compound CC(=O)C.[N+](=O)([O-])C1=C(C=CC(=C1)[N+](=O)[O-])Cl NYYDYGUNUWVDRV-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000005712 elicitor Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229940127022 high-dose drug Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a mung bean extract, which is prepared by the following steps: adding 10-15 times of water into semen Phaseoli Radiati powder, keeping the temperature at 50-60 deg.C for 2-4 hr, grinding, filtering, washing the residue with 5-10 times of water, mixing filtrates, settling for 4-8 hr, filtering, and drying to obtain semen Phaseoli Radiati starch extract; concentrating the filtrate to relative density of 1.02-1.08 (measured at 20 deg.C), adding ethanol until ethanol concentration reaches 40-70%, refrigerating at 4 deg.C, settling for 9-15 hr, filtering, concentrating the filtrate, and drying to obtain semen Phaseoli Radiati total flavone extract; and uniformly mixing the dried mung bean starch extract and the mung bean total flavone extract to obtain the mung bean extract. The extract of the invention has the effects of anti-allergic reaction, detumescence and itching relieving.
Description
Technical Field
The invention belongs to the technical field of pharmacy, and particularly relates to a mung bean extract and a preparation method thereof.
Background
The planting area and the yield of mung beans in China are in the front of the world, and mung beans are regarded by people as having nutritional and medicinal values, so that the mung beans are a resource with great application and development prospects. The mung beans have some research reports on the effects of detoxifying, burning, bacteriostasis, asthma, diabetes, diminishing inflammation, easing pain, reducing blood fat, inhibiting tumors and resisting allergy, but the research reports on the effects of resisting allergic reaction, reducing swelling and relieving itching are not seen yet.
Disclosure of Invention
The invention aims to provide a mung bean extract and a preparation method thereof.
The second purpose of the invention is to provide the application of the mung bean extract.
The mung bean extract is prepared by the following steps:
1) adding 10-15 times of water into mung bean powder by weight, heating to 50-60 ℃, keeping the temperature constant for 2-4 hours, grinding into slurry, filtering, washing filter residues with 5-10 times of water, discarding the filter residues, combining filtrates, settling for 4-8 hours, filtering, drying solids to obtain mung bean starch extract, and reserving the filtrate for later use, wherein the mung bean starch extract contains 50-99% of mung bean starch by weight;
2) concentrating the filtrate under reduced pressure to relative density of 1.02-1.08 (measured at 20 deg.C), adding 95% ethanol into the concentrated solution until ethanol concentration reaches 40-70%, refrigerating at 4 deg.C, settling for 9-15 hr, filtering, concentrating the filtrate, and drying to obtain semen Phaseoli Radiati total flavone extract containing 20-60 wt% of total flavone;
3) and uniformly mixing the dried mung bean starch extract and the mung bean total flavone extract to obtain the mung bean extract.
Preferably, the preparation method of the mung bean extract comprises the following steps:
1) adding 12 times of water into mung bean powder, heating to 50-60 deg.C, keeping the temperature for 3 hr, grinding, filtering, washing the residue with 8 times of water, discarding the residue, mixing the filtrates, settling for 6 hr, filtering, and drying the solid to obtain mung bean starch extract;
2) concentrating the filtrate under reduced pressure to relative density of 1.05 (measured at 20 deg.C), adding 95% ethanol into the concentrated solution until ethanol concentration reaches 60%, refrigerating at 4 deg.C, settling for 12 hr, filtering, concentrating the filtrate, and drying to obtain semen Phaseoli Radiati total flavone extract;
3) mixing semen Phaseoli Radiati starch extract and semen Phaseoli Radiati total flavone extract.
The preparation method of the mung bean extract has the following characteristics: extracting purified mung bean starch with water, and extracting purified mung bean total flavonoids with ethanol, wherein the mung bean extract is a mixture of mung bean starch and mung bean total flavonoids.
As used herein, "concentration" refers to weight concentration, and for example, "95% strength ethanol solution" refers to 95g ethanol per 100g solution.
The extract has the effects of resisting allergic reaction, reducing swelling and relieving itching, has obvious inhibiting effect on acute inflammation of ear swelling of mice caused by xylene, has better inhibiting effect on guinea pig pruritus caused by histamine hydrochloride, can inhibit ear swelling of subacute contact eczema of mice caused by 2, 4-dinitrochlorobenzene, and can obviously reduce the level of I L-4, thereby inhibiting Th (Th)2The function of (a) indicates that the present invention can inhibit delayed allergy.
The invention has the beneficial effects that:
1) the invention provides a mung bean extract and a preparation method thereof, the provided extraction and purification method is simple and convenient, only water and ethanol are used as extraction solvents, toxic substances are not introduced, the obtained extract has high purity, high extraction rate of effective components and good quality, and is safe, and the extract can even be directly used as food raw materials.
2) The mung bean extract obtained by the invention has the effects of resisting allergic reaction, reducing swelling and relieving itching through test verification, has high medicinal value and has wide application prospect in the aspects of medicines, cosmetics and foods.
Detailed Description
The present invention is described in detail below with reference to examples, but the present invention should not be construed as being limited thereto.
Example 1
The preparation method of the mung bean extract comprises the following steps:
1) adding 10 times of water into mung bean powder according to the weight, heating to 50-60 ℃, keeping the temperature for 2 hours, grinding into slurry, filtering, washing filter residues with 5 times of water, discarding the filter residues, combining the filtrates, settling for 4 hours, filtering, drying the solid matters to obtain mung bean starch extract, and reserving the filtrate for later use, wherein the mung bean starch extract contains 50-99% of mung bean starch by weight;
2) concentrating the filtrate under reduced pressure to relative density of 1.02-1.08 (measured at 20 deg.C), adding 95% ethanol into the concentrated solution until ethanol concentration reaches 40%, refrigerating at 4 deg.C, settling for 9 hr, filtering, concentrating the filtrate, and drying to obtain semen Phaseoli Radiati total flavone extract containing 20-60% total flavone;
3) and uniformly mixing the dried mung bean starch extract and the mung bean total flavone extract to obtain the mung bean extract.
Example 2
1) Adding 15 times of water into mung bean powder according to the weight, heating to 50-60 ℃, keeping the temperature for 4 hours, grinding into slurry, filtering, washing filter residues with 10 times of water, discarding the filter residues, combining the filtrates, settling for 8 hours, filtering, drying the solid matters to obtain mung bean starch extract, and reserving the filtrate for later use, wherein the mung bean starch extract contains 50-99% of mung bean starch by weight;
2) concentrating the filtrate under reduced pressure to relative density of 1.02-1.08 (measured at 20 deg.C), adding 95% ethanol into the concentrated solution until ethanol concentration reaches 70%, refrigerating at 4 deg.C, settling for 15 hr, filtering, concentrating the filtrate, and drying to obtain semen Phaseoli Radiati total flavone extract containing 20-60% total flavone;
3) and uniformly mixing the dried mung bean starch extract and the mung bean total flavone extract to obtain the mung bean extract.
Example 3
1) Adding 12 times of water into mung bean powder, heating to 50-60 deg.C, keeping the temperature for 3 hr, grinding, filtering, washing the residue with 8 times of water, discarding the residue, mixing the filtrates, settling for 6 hr, filtering, and drying the solid to obtain mung bean starch extract;
2) concentrating the filtrate under reduced pressure to relative density of 1.05 (measured at 20 deg.C), adding 95% ethanol into the concentrated solution until ethanol concentration reaches 60%, refrigerating at 4 deg.C, settling for 12 hr, filtering, concentrating the filtrate, and drying to obtain semen Phaseoli Radiati total flavone extract;
3) mixing semen Phaseoli Radiati starch extract and semen Phaseoli Radiati total flavone extract.
Example 4 study of drug efficacy
Eczema is a common clinical allergic inflammatory dermatosis, is characterized by various rashes, severe pruritus, repeated attack and easy development into chronic eczema, is one of common and frequent clinical dermatosis, and accounts for 15-30% of the outpatient quantity of dermatology. In terms of pathogenesis, eczema is mainly a delayed allergy caused by complex internal and external elicitors. The invention carries out pharmacodynamic research on aspects of anti-inflammation, itching relieving, anti-allergic reaction and the like, and discusses the pharmacological action of the traditional Chinese medicine for preventing and treating eczema.
1. Relieving itching effect
50 guinea pigs are taken, the right hind feet of the animals are unhaired 24 hours later, the hind feet of the animals are abraded by sand paper, a small amount of blood seepage is used as a degree, then the animals are randomly divided into 5 groups, and the abraded parts are respectively and uniformly coated with 0.5g/kg, 1g/kg and 2g/kg of extracts, 2g/kg of dermatitis or 2g/kg of matrix. After 30min, 0.01%, 0.02% and 0.03% … … 1% histamine hydrochloride 0.05 ml/piece is dropped on the site of the scratch in turn, each time interval is 3min, the histamine concentration of each animal when the animal licks the foot is recorded, and the concentration is the scratchiness threshold, and the results are tested by t (see table 1).
TABLE 1 Effect on Histamen thresholds of Histamen-induced foot of Guinea pigs caused by histamine hydrochloride (X. + -. s)
| Group of | Dosage (g/kg) | Mouse number (only) | Itch threshold (ug/ml) |
| Substrate | 2.0 | 10 | 13.2±5.8 |
| Low dose group of the invention | 0.5 | 10 | 35.1±8.9 |
| Dosage groups of the invention | 1.0 | 10 | 72.8±53.5* |
| High dose group of the invention | 2.0 | 10 | 95.4±101.3* |
| Medicine for treating dermatitis | 2.0 | 10 | 46.2±13.4* |
P <0.05 compared to control group.
As can be seen from Table 1, the extract of the invention can significantly improve the scratchiness threshold of the guinea pig caused by histamine hydrochloride, and has a certain dose-effect relationship.
2. Effect of paraxylene on ear swelling in mice
30 mice are taken and randomly divided into 5 groups, namely a blank control group, a positive control group and high, medium and low dose drug groups, wherein each group comprises 6 mice, the right ear of each group of mice is coated with dimethylbenzene to cause inflammation, each group is 0.05m L for 30min, the low, medium and high dose drug groups are respectively and uniformly coated with extracts of 0.5, 1.0 and 2.0g/kg on the right ear, the positive control group is provided with 2.0g/kg of tramadol cream, the blank control group is provided with a blank matrix of 2.0 g/kg. for 30min, each administration group uses purified water to wash away liquid medicine for cotton ball cleaning, the mice are killed, the left and right ears are respectively cut off, the left and right ears are used as controls, the same parts of the ears are cut by an 8mm puncher in equal area, then the mass is respectively weighed on an electronic balance, the difference of the mass of the left and right ears is used as the swelling degree, and the swelling degree of each group is calculated.
The results are shown in Table 2. Compared with the blank control group, the low dose drug group difference has no statistical significance, and the high and medium dose drug group difference has statistical significance (P <0.01 or P < 0.05). The invention is prompted to have obvious inhibition effect on acute inflammation of mouse auricle swelling caused by xylene.
TABLE 25 xylene swelling in groups of mice
| Group of | Dosage (g/kg) | Mouse number (only) | Poor quality of two ear plates (Mg) |
| Blank control group | 2.0 | 6 | 5.42±1.82 |
| Low dose group of the invention | 0.5 | 6 | 4.15±1.27 |
| Dosage groups of the invention | 1.0 | 6 | 3.68±1.45* |
| High dose group of the invention | 2.0 | 6 | 3.34±1.36* |
| Positive control group | 2.0 | 6 | 3.21±1.04* |
3. Effect on 2, 4-dinitrochlorobenzene-induced delayed hypersensitivity in mice
30 mice are taken, after grouping, the abdomen of each group of mice is unhaired, the area is 3cm × 3cm, the unhairing area is administrated for 1 time, after 24 hours, 7 percent 2, 4-dinitrochlorobenzene acetone solution is injected subcutaneously on the back of each mouse for 0.02m L, after 3 days, sensitization is repeated for 1 time, then each group is respectively applied with medicine for 1 time in the morning and evening, continuously for 8 days, after 9 days, 1 percent 2, 4-dinitrochlorobenzene acetone solution is evenly applied to the right ear of the mouse for 0.03m L, after 24 hours, each group of 6 mice is taken by an eyeball picking method to obtain blood, after whole blood is centrifuged, the content of I L-4 in the blood serum is measured by an enzyme-linked immunosorbent assay (E L ISA), the mice are killed, the left and right ear pieces are taken by a puncher (the diameter is 8mm), the left and right ear pieces are weighed by an electronic balance, and the swelling degree is calculated by taking the difference of the mass of two ears.
The result is shown in table 3, compared with a blank control group, the high, medium and low dose drug groups can improve the right ear swelling condition of mice, the difference has statistical significance (P is less than 0.05), the extract has certain treatment and inhibition effects on the allergic contact dermatitis of the mice induced by the 2, 4-dinitrochlorobenzene, and the content measurement result of I L-4 shows that the high and medium doses of the extract can reduce the level of I L4 in serum, and the difference is not significant compared with the positive control group.
Delayed allergic reaction development in Table 35 mice
| Group of | Dosage (g/kg) | Mouse number (only) | Poor quality of two ear plates (Mg) | IL-4Pg/ml |
| Blank control group | 2.0 | 6 | 8.55±2.64 | 39.14±9.15 |
| Low dose group of the invention | 0.5 | 6 | 5.57±1.98* | 28.12±7.58 |
| Dosage groups of the invention | 1.0 | 6 | 4.85±1.48* | 24.17±4.52* |
| High dose group of the invention | 2.0 | 6 | 1.27±0.34* | 17.31±7.75* |
| Positive control group | 2.0 | 6 | 2.54±0.88* | 20.37±8.25* |
The research proves that the mung bean extract prepared by the invention has the effects of resisting allergy, reducing swelling and relieving itching. Has obvious inhibiting effect on acute inflammation of ear swelling of mice caused by xylene, so that the traditional Chinese medicine composition is suitable for eczema dermatitis. The medicine has better inhibiting effect on the guinea pig itch caused by the histamine hydrochloride, and the itching relieving effect of the medicine is supposed to be related to the reduction of the release of the allergic transmitter.
The pathogenesis of eczema is complex, and at present, the eczema is considered to be a delayed hypersensitivity reaction mediated by T cells caused by internal and external exciting factors. The research result shows that the mung bean extract prepared by the invention is applied to a mouse subacute contact eczema model caused by 2, 4-dinitrochlorobenzene,has similar inhibiting effect to tramadol cream, and can inhibit ear swelling and significantly reduce I L-4 level, thereby inhibiting Th2The function of the mung bean extract prepared by the invention is proved to be capable of inhibiting delayed allergy.
Claims (2)
1. The application of the mung bean extract in preparing the medicine for treating eczema is characterized in that the mung bean extract is prepared according to the following steps:
1) adding 10-15 times of water into mung bean powder according to weight, heating to 50-60 ℃, keeping the temperature constant for 2-4 hours, grinding into slurry, filtering, washing filter residues with 5-10 times of water, discarding the filter residues, combining filtrates, settling for 4-8 hours, filtering, drying solids to obtain mung bean starch extract, and reserving the filtrate, wherein the mung bean starch extract contains 50-99% of mung bean starch by weight;
2) concentrating the filtrate under reduced pressure until the relative density is 1.02-1.08, measuring at 20 deg.C, adding 95 wt% ethanol into the concentrated solution until the ethanol weight concentration reaches 40-70%, refrigerating at 4 deg.C, settling for 9-15 hr, filtering, concentrating the filtrate, and drying to obtain semen Phaseoli Radiati total flavone extract containing 20-60 wt% of total flavone;
3) mixing the dried mung bean starch extract and the mung bean total flavone extract uniformly to obtain a mung bean extract,
the semen Phaseoli Radiati extract has antiallergic, repercussive, and antipruritic effects.
2. The use according to claim 1, characterized in that the mung bean extract is prepared according to the following steps:
1) adding 12 times of water into mung bean powder, heating to 50-60 deg.C, keeping the temperature for 3 hr, grinding, filtering, washing the residue with 8 times of water, discarding the residue, mixing the filtrates, settling for 6 hr, filtering, and drying the solid to obtain mung bean starch extract;
2) concentrating the filtrate under reduced pressure to relative density of 1.05, measuring at 20 deg.C, adding 95 wt% ethanol into the concentrated solution until the ethanol weight concentration reaches 60%, refrigerating at 4 deg.C, settling for 12 hr, filtering, concentrating the filtrate, and drying to obtain semen Phaseoli Radiati total flavone extract;
3) mixing semen Phaseoli Radiati starch extract and semen Phaseoli Radiati total flavone extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610089202.7A CN105687297B (en) | 2016-02-17 | 2016-02-17 | Mung bean extract and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610089202.7A CN105687297B (en) | 2016-02-17 | 2016-02-17 | Mung bean extract and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105687297A CN105687297A (en) | 2016-06-22 |
| CN105687297B true CN105687297B (en) | 2020-07-14 |
Family
ID=56222345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610089202.7A Expired - Fee Related CN105687297B (en) | 2016-02-17 | 2016-02-17 | Mung bean extract and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105687297B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853513A (en) * | 2005-04-29 | 2006-11-01 | 任发政 | Sports beverage with fatigue-releasing function |
| CN102335256A (en) * | 2011-09-22 | 2012-02-01 | 浙江省中药研究所有限公司 | Chinese medicinal herb preparation for lead removing treatment and preparation method thereof |
| CN103242279A (en) * | 2013-05-16 | 2013-08-14 | 陕西科技大学 | Method for extracting and purifying flavonoid substances in hawthorn |
| CN104873569A (en) * | 2015-06-23 | 2015-09-02 | 四川大学 | Method for efficiently and synchronously extracting pueraria starch and flavone |
| CN104910282A (en) * | 2015-07-07 | 2015-09-16 | 山东大学 | Method for producing mung bean/pea starch |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1146877A (en) * | 1995-10-05 | 1997-04-09 | 王登之 | Mung bean protein milk and its preparing process |
-
2016
- 2016-02-17 CN CN201610089202.7A patent/CN105687297B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853513A (en) * | 2005-04-29 | 2006-11-01 | 任发政 | Sports beverage with fatigue-releasing function |
| CN102335256A (en) * | 2011-09-22 | 2012-02-01 | 浙江省中药研究所有限公司 | Chinese medicinal herb preparation for lead removing treatment and preparation method thereof |
| CN103242279A (en) * | 2013-05-16 | 2013-08-14 | 陕西科技大学 | Method for extracting and purifying flavonoid substances in hawthorn |
| CN104873569A (en) * | 2015-06-23 | 2015-09-02 | 四川大学 | Method for efficiently and synchronously extracting pueraria starch and flavone |
| CN104910282A (en) * | 2015-07-07 | 2015-09-16 | 山东大学 | Method for producing mung bean/pea starch |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105687297A (en) | 2016-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857394A (en) | Medicine composition of effective parts for compound Tongmai Chinese medicine oral liquid and its preparing method | |
| CN100998650A (en) | Use of cinnamonum cassia for treating diabetes, its products and preparing method | |
| CN103191245A (en) | Traditional chinese medicine extract and preparation method thereof | |
| CN112494616B (en) | Traditional Chinese medicine composition for inhibiting early development and sexual precocity of children and preparation method and application thereof | |
| CN105687297B (en) | Mung bean extract and preparation method thereof | |
| CN110140812A (en) | Prawn Chinese herbal medicine immunopotentiator and preparation method thereof | |
| CN1788755A (en) | Framberry leaf extract effective part and its composition and uses | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN102327340A (en) | Chinese medicine granular preparation for poultry and preparation method thereof | |
| CN113303472A (en) | Functional beverage produced by using litsea cubeba and preparation process thereof | |
| CN103330918B (en) | Traditional Chinese medicine for curing goose teniasis, as well as preparation method and application thereof | |
| CN103202898A (en) | Traditional chinese medicine composition and preparation method thereof | |
| CN101450162A (en) | Traditional Chinese medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN103239528A (en) | Traditional chinese medicine composition | |
| CN103239529A (en) | Traditional chinese medicine composition | |
| CN102940776B (en) | Compound nervilia fordii granule and preparation method thereof and application in preventing porcine respiratory diseases | |
| CN103202886A (en) | Traditional chinese medicine composition and preparation method thereof | |
| CN102266438A (en) | Antiviral agent for freshwater fishes | |
| CN109010477B (en) | Traditional Chinese medicine foot soaking powder for treating beriberi and preparation method and using method thereof | |
| CN103330752A (en) | Natural medicine composition, preparation method and purpose of natural medicine composition | |
| CN107929344B (en) | Lithospermum compound composition for preventing and treating laryngeal cancer | |
| CN103330753A (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN103330730A (en) | Natural medicine composition and preparation method thereof | |
| CN103223011A (en) | Extract product of traditional Chinese medicine | |
| CN103263471A (en) | Traditional chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: No.88 Aoti Road, Huazhong Industrial Park, Qianjiang City, Hubei Province, 433100 Patentee after: Zhimei (Hubei) biomedical Co.,Ltd. Address before: 430040 Hubei city of Wuhan province Jiangjun Road Street office gold Tan Lu No. 02 (12) Patentee before: YUNTONGBENCAO (WUHAN) BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 433100 No.88 Aoti Road, Huazhong Industrial Park, Qianjiang City, Hubei Province Patentee after: Zhi Mei Tang (Hubei) Chinese Herbal Pieces Co.,Ltd. Address before: 433100 No.88 Aoti Road, Huazhong Industrial Park, Qianjiang City, Hubei Province Patentee before: Zhimei (Hubei) biomedical Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220606 Address after: 433100 No.88 Aoti Road, Huazhong Industrial Park, Qianjiang City, Hubei Province Patentee after: Zhimi (Hubei) Health Technology Co.,Ltd. Address before: 433100 No.88 Aoti Road, Huazhong Industrial Park, Qianjiang City, Hubei Province Patentee before: Zhi Mei Tang (Hubei) Chinese Herbal Pieces Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200714 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |